Advertisement

Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction

Published:April 27, 2018DOI:https://doi.org/10.1016/j.ajem.2018.04.062

      Abstract

      Objective

      The objective of this study was to examine the effects of metoprolol versus diltiazem in the acute management of atrial fibrillation (AF) with rapid ventricular response (RVR) in patients with heart failure with reduced ejection fraction (HFrEF).

      Methods

      This retrospective cohort study of patients with HFrEF in AF with RVR receiving either intravenous push (IVP) doses of metoprolol or diltiazem was conducted between January 2012 and September 2016. The primary outcome was successful rate control within 30 min of medication administration, defined as a heart rate (HR) < 100 beats per minute or a HR reduction ≥ 20%. Secondary outcomes included rate control at 60 min, maximum median change in HR, and incidence of hypotension, bradycardia, or conversion to normal sinus rhythm within 30 min. Signs of worsening heart failure were also evaluated.

      Results

      Of the 48 patients included, 14 received metoprolol and 34 received diltiazem. The primary outcome, successful rate control within 30 min, occurred in 62% of the metoprolol group and 50% of the diltiazem group (p = 0.49). There was no difference in HR control at predefined time points or incidence of hypotension, bradycardia, or conversion. Although baseline HR varied between groups, maximum median change in HR did not differ. Signs of worsening heart failure were similar between groups.

      Conclusions

      For the acute management of AF with RVR in patients with HFrEF, IVP diltiazem achieved similar rate control with no increase in adverse events when compared to IVP metoprolol.

      Keywords

      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lubitz S.A.
        • Benjamin E.J.
        • Ellinor P.T.
        Atrial fibrillation in congestive heart failure.
        Heart Fail Clin. 2010; 6: 187-200https://doi.org/10.1016/j.hfc.2009.11.001
        • Anter E.
        • Jessup M.
        • Callans D.J.
        Atrial fibrillation and heart failure: treatment considerations for a dual epidemic.
        Circulation. 2009; 119: 2516-2525https://doi.org/10.1161/CIRCULATIONAHA.108.821306
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 62e147-239https://doi.org/10.1016/j.jacc.2013.05.019
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • et al.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
        J Am Coll Cardiol. 2014; 64e1-76https://doi.org/10.1016/j.jacc.2014.03.022
        • Page 2nd, R.L.
        • O'Bryant C.L.
        • Cheng D.
        • et al.
        Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association.
        Circulation. 2016; 134: e32-69https://doi.org/10.1161/CIR.0000000000000426
        • Moss A.J.
        • Abrams J.
        • Bigger T.
        • et al.
        The effect of diltiazem on mortality and reinfarction after myocardial infarction.
        N Engl J Med. 1988; 319: 385-392https://doi.org/10.1056/NEJM198808183190701
        • Demircan C.
        • Cikriklar H.I.
        • Engindeniz Z.
        • et al.
        Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation.
        Emerg Med J. 2005; 22 (doi:22/6/411 [pii]): 411-414
        • Fromm C.
        • Suau S.J.
        • Cohen V.
        • et al.
        Diltiazem vs. metoprolol in the management of atrial fibrillation or flutter with rapid ventricular rate in the emergency department.
        J Emerg Med. 2015; 49: 175-182https://doi.org/10.1016/j.jemermed.2015.01.014
        • Scheuermeyer F.X.
        • Grafstein E.
        • Stenstrom R.
        • et al.
        Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness.
        Acad Emerg Med. 2013; 20: 222-230https://doi.org/10.1111/acem.12091
        • Harris P.A.
        • Taylor R.
        • Thielke R.
        • Payne J.
        • Gonzalez N.
        • Conde J.G.
        Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support.
        J Biomed Inf. 2009; 42: 377-381
        • Olsson T.
        • Lind L.
        Comparison of the rapid emergency medicine score and APACHE II in nonsurgical emergency department patients.
        Acad Emerg Med. 2003; 10: 1040-1048https://doi.org/10.1197/S1069-6563(03)00342-7
        • Goldenberg I.F.
        • Lewis W.R.
        • Dias V.C.
        • Heywood J.T.
        • Pedersen W.R.
        Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure.
        Am J Cardiol. 1994; 74 (doi:0002-9149(94)90580-0 [pii]): 884-889
        • Kelly J.P.
        • Cooper L.B.
        • Gallup D.
        • et al.
        Implications of using different definitions on outcomes in worsening heart failure.
        Circ Fail. 2016; 9https://doi.org/10.1161/CIRCHEARTFAILURE.116.003048
        • Butler J.
        • Gheorghiade M.
        • Kelkar A.
        • et al.
        In-hospital worsening heart failure.
        Eur J Heart Fail. 2015; 17: 1104-1113https://doi.org/10.1002/ejhf.333
        • Khatchi F.
        • Nagaband S.
        • Shuster J.
        • Novak E.
        • Joseph S.
        Treating rapid atrial fibrillation in acute decompensated heart failure: metoprolol and diltiazem are equally safe, yet metoprolol increases conversion to sinus rhythm.
        J Card Fail. 2014; 20: S41
        • Kulick D.L.
        • McIntosh N.
        • Campese V.M.
        • et al.
        Central and renal hemodynamic effects and hormonal response to diltiazem in severe congestive heart failure.
        Am J Cardiol. 1987; 59 (doi:0002-9149(87)90862-9 [pii]): 1138-1143
        • Walsh R.W.
        • Porter C.B.
        • Starling M.R.
        • O'Rourke R.A.
        Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure.
        J Am Coll Cardiol. 1984; 3: 1044-1050
        • Materne P.
        • Legrand V.
        • Vandormael M.
        • Collignon P.
        • Kulbertus H.E.
        Hemodynamic effects of intravenous diltiazem with impaired left ventricular function.
        Am J Cardiol. 1984; 54 (doi:S0002-9149(84)80199-X [pii]): 733-737
        • Bhatt A.S.
        • DeVore A.D.
        • DeWald T.A.
        • Swedberg K.
        • Mentz R.J.
        Achieving a maximally tolerated β-blocker dose in heart failure patients: is there room for improvement?.
        J Am Coll Cardiol. 2017; 69: 2542-2550https://doi.org/10.1016/j.jacc.2017.03.563